Column

Viewpoint

Chemotherapy Shortages: When is Enough, Enough?

05/06/2016

Shortages of life-saving chemotherapy agents and supportive care drugs have presented physicians treating children with cancer with difficult decisions regarding drug allocation and prioritization. Guidelines...

...

05/06/2016

Journal of Clinical Pathways

Pharma Insights

Companion Diagnostics and Complementary Diagnostics in Clinical Practice: Better Medicine or Competitive Disadvantage?

05/06/2016

David Parker , PhD;

Larry Blandford , PharmD;

We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in...

We are...

05/06/2016

Journal of Clinical Pathways

Clinical Pathways GPS

Hitting Each Component of the Triple Aim Along the Clinical Pathway

05/06/2016

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Seth Gordon , MBA;

Scott Guerin , PhD;

The concept of the Triple Aim—improving the experience of care, reducing the costs of care, and improving the health of populations—is increasingly becoming important to drug manufacturers, who must demonstrate how...

The...

05/06/2016

Journal of Clinical Pathways

Editor's Page

For Buy-In of the Clinical Pathways Concept, Transparency Is Key

05/06/2016

Winston Wong , PharmD;

Essential to the success of clinical pathways is transparency of the development process. This includes transparency regarding the clinical evidence reviewed, the economic evaluations made, and the process by which...

...

05/06/2016

Journal of Clinical Pathways

Clinical Pathways GPS

Adding Patient Navigation to the Clinical Pathway for Alzheimer Disease

04/11/2016

Ruth Gay ;

David Digby ;

Harold Freeman , MD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Mary Michael ;

Patient navigation has proven capable of both improving health outcomes and decreasing costs to the health care system. Although the use of patient navigation in the context of cancer care has been described...

...

04/11/2016

Journal of Clinical Pathways

Pharma Insights

When Medication Price Deflates Perception of Therapeutic Effect

04/11/2016

Larry Blandford , PharmD;

Stephen C. Carter , BSc;

Manufacturers set prices for their products that best represent their value while providing the greatest financial return on investment. Thus, conventional wisdom would suggest that manufacturers set a higher price...

...

04/11/2016

Journal of Clinical Pathways

Editor's Page

Value in Health Care: In the Eye of the Beholder

04/08/2016

Winston Wong , PharmD;

Value is defined differently depending on who is defining it. Still, whether value is being defined by the health care provider, the payer, the patient, or industry, the importance of evidence-based treatment...

Value...

04/08/2016

Journal of Clinical Pathways

Counterpoint

ASCO Policy Statement on Clinical Pathways in Oncology Represents Great Progress for Clinical Pathways

03/08/2016

Winston Wong , PharmD;

The ASCO Policy Statement on Oncology Clinical Pathways shows how far clinical pathways have come in gaining acceptance among providers and supports their potential for improving the value of cancer care. The...

The...

03/08/2016

Journal of Clinical Pathways

Viewpoint

Greater Alignment Among Oncology Clinical Pathways is Needed

03/08/2016

Edward Stepanski , PhD;

A single, consensus-driven approach to oncology clinical pathways shared across payers appears to be a logical step if these approaches are to be indeed evidence-based and if administrative burden is to be managed...

A...

03/08/2016

Journal of Clinical Pathways

Clinical Pathways GPS

Calling it Quits: Addressing Treatment Discontinuation on a Clinical Pathway

03/08/2016

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Donald Ohloma , MS;

Discontinuation of treatment should be considered whenever treatment benefits are exceeded by their burden. When and how patients should be discontinued from treatment, however, may not necessarily be addressed by a...

...

03/08/2016

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products